[go: up one dir, main page]

MX2017016492A - Metodos para tratar tumores solidos usando terapia de combinacion de nanoparticula del inhibidor del objetivo mamifero de la rapamicina (mtor). - Google Patents

Metodos para tratar tumores solidos usando terapia de combinacion de nanoparticula del inhibidor del objetivo mamifero de la rapamicina (mtor).

Info

Publication number
MX2017016492A
MX2017016492A MX2017016492A MX2017016492A MX2017016492A MX 2017016492 A MX2017016492 A MX 2017016492A MX 2017016492 A MX2017016492 A MX 2017016492A MX 2017016492 A MX2017016492 A MX 2017016492A MX 2017016492 A MX2017016492 A MX 2017016492A
Authority
MX
Mexico
Prior art keywords
methods
mtor inhibitor
combination therapy
solid tumors
treating solid
Prior art date
Application number
MX2017016492A
Other languages
English (en)
Inventor
P Desai Neil
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2017016492A publication Critical patent/MX2017016492A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención tiene relación con métodos y composiciones para el tratamiento de un tumor sólido administrando composiciones que comprenden nanopartículas que comprenden un inhibidor de mTOR (como un fármaco limus, por ejemplo, sirolimus o un derivado de mismo) y una albúmina en combinación con composiciones que comprenden un segundo agente terapéutico.
MX2017016492A 2015-06-29 2016-06-29 Metodos para tratar tumores solidos usando terapia de combinacion de nanoparticula del inhibidor del objetivo mamifero de la rapamicina (mtor). MX2017016492A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186325P 2015-06-29 2015-06-29
PCT/US2016/040202 WO2017004267A1 (en) 2015-06-29 2016-06-29 Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy

Publications (1)

Publication Number Publication Date
MX2017016492A true MX2017016492A (es) 2018-08-16

Family

ID=57609103

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016492A MX2017016492A (es) 2015-06-29 2016-06-29 Metodos para tratar tumores solidos usando terapia de combinacion de nanoparticula del inhibidor del objetivo mamifero de la rapamicina (mtor).

Country Status (14)

Country Link
US (2) US20180153863A1 (es)
EP (1) EP3313382A4 (es)
JP (1) JP2018521058A (es)
KR (2) KR20180019229A (es)
CN (1) CN107921006A (es)
AU (1) AU2016287508B2 (es)
CA (1) CA2990726A1 (es)
CL (1) CL2017003457A1 (es)
EA (1) EA201890146A1 (es)
HK (1) HK1247093A1 (es)
IL (1) IL256333B2 (es)
MX (1) MX2017016492A (es)
NZ (1) NZ738929A (es)
WO (1) WO2017004267A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5933893B2 (ja) 2006-12-14 2016-06-15 アブラクシス バイオサイエンス， エルエルシー ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
ME03596B (me) 2009-04-15 2020-07-20 Abraxis Bioscience Llc Kompozicije nanočesтica bez priona i postupci povezani sa njima
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CA2903454A1 (en) 2013-03-12 2014-10-02 Abraxis Bioscience, Llc Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
US20180311203A1 (en) * 2015-01-12 2018-11-01 Emcure Pharmaceuticals Limited Liquid formulation of cabazitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
HK1254398A1 (zh) * 2015-06-29 2019-07-19 Abraxis Bioscience, Llc 納米粒子組合物的生物標誌物
EA036790B1 (ru) 2015-06-29 2020-12-22 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способ лечения злокачественной пекомы
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US10841364B2 (en) * 2017-03-27 2020-11-17 International Business Machines Corporation Using and comparing known and current activity states to determine receptiveness
EP3641772B1 (en) * 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
US20190184031A1 (en) * 2017-12-19 2019-06-20 Abraxis Bioscience, Llc Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
EP3768268A4 (en) 2018-03-20 2022-02-23 Abraxis BioScience, LLC METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE
AU2019237257A1 (en) * 2018-03-23 2020-10-15 ISR Immune System Regulation Holding AB (publ) Combinations of macrolide compounds and immune checkpoint inhibitors
KR20210024471A (ko) * 2018-05-22 2021-03-05 아브락시스 바이오사이언스, 엘엘씨 폐고혈압을 치료하기 위한 방법 및 조성물
US10350226B1 (en) * 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections
WO2020123481A1 (en) * 2018-12-10 2020-06-18 Celator Pharmaceuticals Inc. Combination formulations of taxanes and mtor inhibitors
CN120267635A (zh) * 2019-03-19 2025-07-08 阿布拉科斯生物科学有限公司 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病
CN110055331B (zh) * 2019-05-10 2023-05-02 人和未来生物科技（长沙）有限公司 一种用于膀胱癌辅助诊断或筛查的试剂盒及其应用
US20220395578A1 (en) * 2019-06-28 2022-12-15 The Board Of Regents Of The University Of Oklahoma Therapeutic annexin-drug conjugates and methods of use
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN
MX2022005715A (es) * 2019-11-11 2022-09-19 Abraxis Bioscience Llc Biomarcadores para composiciones de nanoparticulas.
CN117045800A (zh) * 2022-05-06 2023-11-14 上海科技大学 mTOR抑制剂增强靶向蛋白降解药物功效的应用
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
WO2024228964A1 (en) * 2023-04-30 2024-11-07 Aadi Bioscience, Inc. Treatments comprising an mtor inhibitor nanoparticle composition
WO2025075314A1 (ko) 2023-10-06 2025-04-10 오스템임플란트 주식회사 치과용 임플란트 및 이를 포함하는 치과용 임플란트 조립체
CN119770670B (zh) * 2024-12-27 2025-09-23 西安交通大学医学院第一附属医院 一种蛋白微球抑制剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101415409B (zh) * 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
CA3201293A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
AU2013204187B2 (en) * 2007-03-07 2015-10-01 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
EP2968191B1 (en) * 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
TW201526897A (zh) * 2013-04-17 2015-07-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法

Also Published As

Publication number Publication date
IL256333A (en) 2018-02-28
CA2990726A1 (en) 2017-01-05
WO2017004267A1 (en) 2017-01-05
HK1247093A1 (zh) 2018-09-21
CN107921006A (zh) 2018-04-17
KR20180019229A (ko) 2018-02-23
NZ738929A (en) 2024-01-26
CL2017003457A1 (es) 2018-05-11
IL256333B2 (en) 2023-03-01
US20180153863A1 (en) 2018-06-07
IL256333B (en) 2022-11-01
AU2016287508B2 (en) 2021-10-14
US20230263779A1 (en) 2023-08-24
AU2016287508A1 (en) 2018-02-01
EP3313382A4 (en) 2019-03-06
KR20240090657A (ko) 2024-06-21
EA201890146A1 (ru) 2018-06-29
JP2018521058A (ja) 2018-08-02
EP3313382A1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2017016491A (es) Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2016007351A (es) Terapia de combinacion para tratar cancer.
NZ700759A (en) Combination therapy for treating cancer
TW201613887A (en) Antiproliferative compounds and methods of use thereof
WO2016025635A3 (en) Combination therapy for treating cancer
MY162903A (en) Methods of treatment of pancreatic cancer
SG10201902664RA (en) Combination therapy for treating cancer
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
WO2014194254A8 (en) Treatment of cancers using pi3 kinase isoform modulators
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2016043874A3 (en) Combination therapy for treating cancer
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
PH12016501527B1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
MX2019003694A (es) Metodos para tratar cancer del tracto biliar.
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
HK1259026A1 (zh) 用於治疗癌症的抗趋除剂的局部递送
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
HK1229709A1 (en) Combination therapy for treating cancer